Company Quick10K Filing
OWC Pharmaceutical Research
10-Q 2019-09-30 Filed 2019-11-13
10-Q 2019-06-30 Filed 2019-08-13
S-1 2019-05-31 Public Filing
10-Q 2019-03-31 Filed 2019-05-15
10-K 2018-12-31 Filed 2019-04-01
10-Q 2018-09-30 Filed 2018-11-08
10-Q 2018-06-30 Filed 2018-08-16
S-1 2018-06-14 Public Filing
10-Q 2018-03-31 Filed 2018-05-15
10-K 2017-12-31 Filed 2018-04-16
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-06-30 Filed 2017-08-21
10-Q 2017-03-31 Filed 2017-05-18
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2016-11-14
10-Q 2016-06-30 Filed 2016-08-29
10-Q 2016-03-31 Filed 2016-05-16
10-K 2015-12-31 Filed 2016-04-14
10-Q 2015-09-30 Filed 2015-11-13
10-Q 2015-06-30 Filed 2015-08-17
10-Q 2015-03-31 Filed 2015-05-15
10-K 2014-12-31 Filed 2015-04-01
10-Q 2014-09-30 Filed 2014-11-14
10-Q 2014-06-30 Filed 2014-07-29
10-Q 2014-03-31 Filed 2014-05-08
10-K 2013-12-31 Filed 2014-03-21
10-Q 2013-09-30 Filed 2013-11-07
10-Q 2013-06-30 Filed 2013-08-12
10-Q 2013-03-31 Filed 2013-05-14
10-K 2012-12-31 Filed 2013-04-15
8-K 2020-03-30 Other Events, Exhibits
8-K 2020-03-19 Sale of Shares, Other Events, Exhibits
8-K 2020-03-12 Officers
8-K 2020-03-09 Officers
8-K 2019-12-20 Shareholder Rights, Amend Bylaw, Shareholder Vote
8-K 2019-12-12 Other Events
8-K 2019-11-13 Sale of Shares, Exhibits
8-K 2019-11-13 Other Events
8-K 2019-10-22 Sale of Shares, Exhibits
8-K 2019-10-07 Other Events
8-K 2019-09-16 Other Events
8-K 2019-08-29 Sale of Shares, Exhibits
8-K 2019-07-24 Other Events
8-K 2019-05-23 Sale of Shares, Exhibits
8-K 2019-05-06 Other Events
8-K 2019-04-15 Other Events
8-K 2019-04-04 Shareholder Vote
8-K 2019-03-13 Other Events
8-K 2019-02-22 Sale of Shares, Exhibits
8-K 2019-02-05 Sale of Shares, Exhibits
8-K 2019-02-01 Officers
8-K 2019-01-29 Other Events
8-K 2018-12-31 Other Events
8-K 2018-11-30 Other Events
8-K 2018-11-30 Other Events
8-K 2018-10-22 Other Events
8-K 2018-08-21 Officers, Exhibits
8-K 2018-08-01 Other Events
8-K 2018-06-28 Other Events
8-K 2018-06-13 Other Events
8-K 2018-04-30 Enter Agreement, Sale of Shares, Shareholder Rights, Amend Bylaw, Exhibits
8-K 2018-03-08 Other Events, Exhibits
8-K 2018-03-05 Other Events, Exhibits
8-K 2018-02-19 Officers, Exhibits

OWC Pharmaceutical Research Financials

OWCP Metrics, Comps, Filings

Quarterly | Annual

Business

We are an early stage medical cannabis research and development company that applies conventional pharmaceutical research protocols and disciplines to the field of medical cannabis with the objective of establishing a leadership position in the research and development of medical cannabis therapies, products and delivery technologies. We are currently engaged in the research and development and have conducted trials on the efficacy of cannabis-based medical products (the “Cannabis-Based Medical Products”) commencing with our cannabis-based topical ointment for the treatment of psoriasis. In addition, we also are pursuing the use of our Cannabis-Based Medical Products for the treatment of multiple myeloma, post-traumatic stress disorder (“PTSD”), chronic pain and fibromyalgia, and have made significant advancements in the development of a cannabis soluble tablet delivery system that could have applications for other indications. We are also capable of providing consulting and advisory services to governmental and private entities to assist them with developing and implementing tailor-made, comprehensive medical cannabis programs, although we have not generated any revenues from such services to date.

We have been engaged in research and development and consulting and advisory activities through our wholly-owned Israeli subsidiary, One World Cannabis Ltd., since July 2014. To date, we have entered into binding agreements with major hospitals and medical research facilities in Israel for the purpose of conducting research studies and trials related to the development and use of Cannabis-Based Medical Products for the treatment of multiple myeloma, psoriasis, PTSD, chronic pain and fibromyalgia, and for the development of a cannabis soluble tablet delivery system.

On January 29, 2019 we reported positive Phase 1 safety data for our medical grade cannabis MGC ointment for the treatment of skin diseases. No severe adverse events were observed in the trial.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
OWC Pharmaceutical Research (OWCP) 0 0% -0.2 362% 1,773 1,467 100 0 6,420 6,420 -1,465
Headhunter Group (HHR)
United States Short Oil Fund (DNO) 0 -0% 0.0 0 0 -600 0 -1,856 -1,856 -0
Immune Therapeutics (IMUN) 0 0.0 -29,381% 8 13,479 0 0 -2,476 -2,475 -6
Juniper Industrial (JIH)
PositiveID Corp (PSID)
Live Current Media (LIVC) 0 2.8 -26% 418 108 0 0 -110 -109 -306
Sun Pacific Holding (SNPW) 0 30% -17.5 -20% 6,669 10,975 260 77 -1,301 -315 5,510
Digatrade Financial (DIGAF) 0 0% 527 778 0 0 0 0 0
Lingerie Fighting Championships (BOTY) 0 -49% 0.2 -8,950,200% 23 -11 90 -10 -2
New Century Resources (NCRE) 0 0.0 0 205 0 0 -18 -17 -0
Arete Industries (ARET)
Renewable Energy Acquisition (REAC) 0 0.0 2,353,600% 0 0 -24 -22 -0
Sundial Growers (SNDL)
Energy Transfer Operating (ETP) 0 27% 5.8 4% 95,247,000 59,636,000 40,493,000 10,886,000 3,786,000 8,016,000 46,523,000
Blue Line Protection Group (BLPG) 0 40% 0.0 -189% 1,661 5,917 3,017 1,201 -3,138 -2,534 -19
ABCO Energy (ABCE) 0 38% 0.1 -173% 411 1,359 1,627 622 -713 -502 -28
Guided Therapeutics (GTHP) 0 332% 0.1 1,462% 404 16,413 28 93 5,908 6,835 439
Endonovo Therapeutics (ENDV) 0 73% -0.8 -301% 3,414 19,980 204 150 -10,268 -9,617 7,448
Dominovas Energy (DNRG)

Balance Sheet ($'000)2013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash4178298471,3891,4691,166799532357266162904721,3801,1139716924,6494,2193,4642,8001,8401,465
Accounts Receivable
Inventory
PP&E26292928262318371411104633333373353331
Assets4178298471,4371,5231,1958405684303432391304972,0761,4131,2181,0617364,7744,3123,5532,9492,3351,773
Accounts Payable12173753459853640657112823198163104286
Long-Term Debt
Liabilities741021284981604056471083153512373964481762082702346,4246,76810,76710,2511,7501,467
Stockholders' Equity-57-947981,3561,4631,15478552132328-150-1071011,6271,2371,010791502-2,183-3,791-9,440-10,242-3,043-4,008
Income Statement ($'000)2013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue00000000000000050000010001000
Cost of Revenue
Gross Profit
R&D0000000160997797-15373530-2443421694-782155273126285320168
SG&A59149149472-1074,3541543055333112452228475-2,3871,4011,5581,106-6,851821756543498395519
Tax0000000000
Net Income-71-170-42-35-509-4,354-315-405-408-233-314-80-141-1,658-1,435-445-1,201-1,477-977-2,990-991-1,0007,707-287
Cash Flow ($'000)2013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-19-49-14-9-17-22-289-274-3871,138-1,795-173-172-100-126-131-191-395-274-326-371-949-427-665-955-372
Cash Investing-6-2-2010-10-2-6-10-10-20-20
Cash Financing156354238608593539002410710505251,768-273101891054,9180000